[Click e-Stock] "PharmaResearch Expected to Recover Growth in Q4"

On November 12, Daol Investment & Securities analyzed that PharmaResearch's third-quarter results for this year met market expectations.

In the third quarter, PharmaResearch posted sales of 135.4 billion won and operating profit of 61.9 billion won. Compared to the same period last year, these figures increased by 52% and 77%, respectively.

Park Jonghyun, a researcher at Daol Investment & Securities, explained, "Profitability improved as sales from subsidiaries with lower cost ratios increased," adding, "Domestic sales of medical devices decreased by 6% quarter-on-quarter due to a shortage of procedures."

He continued, "Exports recorded 19.6 billion won, down 19% from the previous quarter," and added, "This was a temporary decline due to strengthened control and management of distributors that had been distributing to regions without sales rights."

Park estimated, "In the fourth quarter of this year, sales will reach 153 billion won and operating profit will be 64.7 billion won," predicting that "these figures will increase by 48% and 92%, respectively, compared to last year."

He analyzed, "Unlike the third quarter, where sales declined quarter-on-quarter due to temporary factors, sales are expected to increase in the fourth quarter," and added, "PharmaResearch's dominance in the Rejuran market remains solid."

This content was produced with the assistance of AI translation services.